Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell’epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0

Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell’epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0–F2

Published:2013-10-23 Issue:3 Volume:15 Page:111-122
ISSN:1590-9158
Container-title:PharmacoEconomics Italian Research Articles
language:it
Short-container-title:PharmacoEcon Ital Res Artic

Author:

Ravasio R.,Tomic R.,Deodato B.,Bruno R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy

Link

http://link.springer.com/content/pdf/10.1007/s40276-013-0010-6.pdf

Reference21 articles.

1. Bacon BR, Gordon SC, Lawitz E, et al (HCV RESPOND-2 Investigators). Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.

2. Zeuzem S, Andreone P, Pol S, et al (REALIZE Study Team). Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.

3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.

5. Indicazioni dell’Associazione Italiana per lo Studio del Fegato (AISF) sull’uso della triplice terapia (interferone-peghilato alfa + ribavirina + inibitore della proteasi di prima generazione) per il trattamento dei pazienti con epatite cronica da HCV genotipo 1. Documento pubblicato online in data 24 aprile 2013. http://www.webaisf.org/ .

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Impact of Therapeutic Choices: The Case of Incretins;Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish;2014-07